SEC Form 4 · accession 0000950138-16-001491
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew K Harbaugh
Officer — Exec. VP & CFO
Period of report
Dec 3, 2016
Accepted (ET)
Dec 6, 2016 · 8:22 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Dec 3, 2016 | F | 297 | $53.61 | D | 54,512 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 191 shares acquired between July 5, 2016 and September 30, 2016, under the Mallinckrodt employee stock purchase plan.